BLU-945 Monotherapy and Combination With Osimertinib in Previously Treated Patients With Advanced EGFR-Mutant (EGFRm) NSCLC in Phase 1/2 SYMPHONY Study
Titel:
BLU-945 Monotherapy and Combination With Osimertinib in Previously Treated Patients With Advanced EGFR-Mutant (EGFRm) NSCLC in Phase 1/2 SYMPHONY Study
Auteur:
Elamin, Y. Nagasaka, M. Shum, E. Bazhenova, L. Rotow, J. Spigel, D.R. Tan, D.S.W. Zalutskaya, A. Albayya, F. Reckamp, K.L.